CME Opportunities

CME Opportunities

View More Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

All Oncology News

OncLive News Network®

Insights MedNews Week OncChats OncLive News Network®OncLive TV Peer Exchange Podcasts Rapid Readouts

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Giants of Cancer Care CME/CE Scientific Interchanges State of the Science Summit / IPC National Fellows Forum Webinars

Partners Publications

Consensus Viewpoints

Interactive Tools

Consensus Viewpoints Interactive Tools Sponsored

Biomarker Consortium Subscribe

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

OncLive SOSS

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Treatment Approaches in Non-Driver Lung Adenocarcinoma

EP. 1: First-Line Chemotherapy Options in Lung Adenocarcinoma

October 31st 2016

EP. 2: Non-Driver Mutation Non-Squamous NSCLC

October 31st 2016

EP. 3: Potential Upfront and Maintenance Strategies in NSCLC

October 31st 2016

EP. 4: Options in Second-Line Non-Squamous NSCLC

October 31st 2016

EP. 5: PD-L1 Status in Second-Line Lung Adenocarcinoma

October 31st 2016

EP. 6: Non-Driver NSCLC: Clinical Decisions in Rapidly Progressing Disease

October 31st 2016

EP. 7: Differentiating Among Anti-VEGF Therapies in Lung Adenocarcinoma

October 31st 2016

EP. 8: Lung Adenocarcinoma: Patient Selection With Ramucirumab vs Nintedanib

October 31st 2016

EP. 9: Practical Implications of the LUME-Lung 1 Findings

October 31st 2016

EP. 10: Practical Considerations With Nintedanib in Lung Adenocarcinoma

October 31st 2016

<
1
2
>

x